Celecoxib in Parkinson Disease as Adjuvant Therapy

Recruiting now · Phase 1/Phase 2

Conditions studied: Parkinson Disease

In brief

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Key facts

Study ID

NCT07246278

Run by

Tanta University

People needed

80

Starts

2025-11-20

Expected to finish

2026-11-28

Last updated by the study team

2025-12-05

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Both male and female will be included.
• Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

You may not qualify if…

• Breast feeding
• Patients with significant liver and kidney function abnormalities.
• Alcohol and / or drug abusers.
• Patients with known allergy to the study medications
• Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).
• Pregnant women and women with planned pregnancy.
• Patients who are currently using other anti-inflammatory drugs.

Where it is running

• Tanta Unuversity — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.